Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : 50% Gains Investing -- Ignore unavailable to you. Want to Upgrade?

To: Dale Baker who wrote (7880)	6/23/1999 2:54:00 PM
From: Steeliejim	Read Replies (1) \| Respond to of 118717

Why Dale, O' cool, objective one. I'm surprised at you. Last year I might have gone ahead and bought based on an emotional knee jerk reaction to the kind of postings I've been seeing on BXM's Yahoo board. As much as I think the product is good, I am worried about end user sales. The large short postition may be misplaced. But the last time I followed something similar, it was SFSK and the shorts were vindicated at earnings. Web might remember the same thing at MRVC. BXM may indeed blow away earnings. But I think if that happens the rebound will be more than a one day wonder. Did you get into ANIK? It's creeping up. FDA approval is still months away, but it looks like traders are positioning themselves. VMIX--got killed over earnings warning re. higher expenses for moving to larger distribution facitlities. Tae Kim: Are you still in? Could be a good value play. Bounced today on good vol. Jim

To: Dale Baker who wrote (7880)	6/24/1999 7:42:00 AM
From: gringodoc	Read Replies (2) \| Respond to of 118717

Dale: IMO, Biomatrix's Synvisc is no panacea to osteoarthritis. I've had a short position in BXM for several months and I'm looking for single digits in the future. Two rheumatologists to whom I've spoken stopped using the product months ago because of mediocre response and also because they did not wish to carry expensive inventory in their office. None of the medical literature that I've reviewed has impressed me with this one. Some insurance companies are also balking at paying for the product. Personally, I feel that BXM will follow the VVUS story and chart to the tee: »»» both firms are essentially one trick ponies »»» both firms have FDA approved products that work, but work poorly »»» both MUSE and Synvisc are invasive Rx's »»» the stocks of both firms popped significantly when FDA approved their manufacturing site and they brought production in house. '''''''''' I feel that demand has been largely overestimated and that Biomatrix will now be saddled with excess capacity etc etc etc Gringo